Zhengping Zhuang, M.D., Ph.D.
- Center for Cancer Research
- National Cancer Institute
- Building 37, Room 1000
- Bethesda, MD 20892
Dr. Zhuang is a research scientist leading the Cancer Stem Cell Biology Program within the NCI Center for Cancer Research’s Neuro-Oncology Branch (NOB). His program uses critical patient observations to drive bench research, which is then translated for clinical use. He has investigated the role of hypoxia signaling in tumor pathophysiology throughout his career, which led him to discover a unique neuroendocrine tumor syndrome caused by a somatic gain-of-function mutation in the genes encoding hypoxia-inducible factor 2α (HIF2α), causing Pacak-Zhuang syndrome.
This model has helped him explore the role of hypoxia signaling in tumor pathophysiology, including brain tumors. His lab is currently investigating hypoxia signaling, IDH mutations, and p53 mutations in brain tumor development and progression—using patient-derived stem cell and neuroprogenitor cell in vitro and in vivo models. His lab is also applying these findings to the development of novel therapeutic agents, including immunomodulating agents and CAR-T cell therapies for brain tumors. Some of these agents have already entered clinical trials at the NOB.
Areas of Expertise
1) Cancer biology 2) Cancer genetics 3) Translational research 4) Astrocytoma 5) Hypoxia-inducible factor 2 6) Neuro-oncology
Information for Patients
Learn about our multidisciplinary approach to patient care, our clinical trials and the highly specialized care teams who lead them.
The root of Dr. Zhuang’s research is based on the inherited and somatic mutations that result in cancer. He aims to understand how these mutations contribute to the development and progression of tumors, particularly in brain tumors. His laboratory utilizes clinical, translational, and basic approaches to study the basic science as a foundation for understanding the pathological changes present in tumors. He has three ongoing multidisciplinary projects: 1) investigating hypoxia signaling and tumor development, 2) examining the impact of patient-derived IDH1 mutant mosaicism on brain tumor development, and 3) developing therapeutics for cancers of the central nervous system.
The first project investigates gain-of-function mutations in the gene encoding the hypoxia inducible factor 2α (HIF2α) protein, which was first found in a combined clinical and scientific effort culminating in the discovery of Pacak-Zhuang syndrome. Using mouse models, Dr. Zhuang’s lab is investigating the unusual phenotypes recently identified in patients with Pacak-Zhuang syndrome, including sexual dimorphism and HIF2α genomic imprinting. These studies will substantially advance our understanding of HIF2α’s impact on biology and pathobiology, including Pacak-Zhuang syndrome and hypoxia signaling in brain tumors.
The second project began with a critical observation in identical twins with low-grade IDH-mutant gliomas. This observation showed that an IDH1 mutation in early development can have two possible outcomes: 1) it may remain quiescent or in the “pre-tumor state” throughout development, or 2) it may acquire additional mutations that allow the cell to transform into a tumor. Because Dr. Zhuang discovered glutamine synthestase, which is important in IDH-mutant tumors (and astrocytoma specifically), his lab is primed to deduce the basic physiology resulting in a brain tumor. His team used deep PCR techniques to show that an inherent and embryonic IDH1 mutation triggered a tumor with p53. His lab has also used induced pluripotent stem (iPS) cells to determine how IDH mutations drive tumor growth by studying the 2-hydroxyglutarate (2-HG) and glutamate cycle.
The third project has several arms: First, Dr. Zhuang’s lab is working to develop an immunomodulator called LB100, which acts by inhibiting protein phosphatase 2A and has entered clinical trials. Second, his lab has developed CAR-T cells targeting the hypoxia signaling downstream product, carbonic anhydrase IX. Third, he has developed a modulator of HIF2a, which has allowed to his lab to further explore this pathway.
Transgenic Mouse Model of Polycythemia, Paraganglioma, and Somatostatinoma with Epas1 Gain-of-function Mutation.
Pharmacologic inhibition of protein photastase-2A, with novel inhibitor LB-100, achieves durable immune-mediated antitumor activity when combined with PD-1 blockade.
β-catenin signaling initiates the activation of astrocytes and its dysregulation contributes to the pathogenesis of astrocytomas
Zhengping Zhuang, M.D., Ph.D.
Dr. Zhuang received his Doctor of Medicine degree from Shanghai Jiao Tong University School of Medicine (formerly Shanghai Second Medical University) in China. He completed a short residency in general surgery at Ruijin Hospital before moving to the United States to pursue a Ph.D. in pharmacology at Wayne State University in Detroit, Michigan. Following his doctorate, he was a postdoctoral fellow at Massachusetts General Hospital for a year. Shortly thereafter, he relocated back to Michigan to be a resident in translational medicine at Henry Ford Hospital. He then served as a research associate at the University of Michigan, and moved to the NIH in 1993 as a resident in anatomic physiology at NCI’s Department of Pathology. He was named a special expert and staff pathologist for the Surgical Neurology Branch—a position he held for seventeen years. In 2017, Dr. Zhuang joined the NCI Center for Cancer Research’s Neuro-Oncology Branch (NOB) in 2017 as a senior investigator.
In addition to his extensive research experience and tenure in multiple branches at the NIH, Dr. Zhuang is also licensed to practice medicine in the District of Columbia, and holds a completion certificate for an anatomic pathology residency. He also currently holds five patents (11 pending) that highlight the novelty of his research endeavors.
Honors, Awards and Leadership
- Isolation of cellular material under microscopic visualization using an adhesive/extraction reagent tipped probe, US Patent #5843644
- Isolation of cellular material under microscopic visualization, US Patent #6010888
- Isolation of cellular material under microscopic visualization, US Patent #6204030
- Isolation of cellular material under microscopic visualization, US Patent #6569639
- The gene associated with Multiple Endocrine Neoplasia type 1, menin polypeptides, and uses thereof, US Patent # 7358347
- The Federal Technology Transfer Award, 2019
- The Federal Technology Transfer Award, 2018
- Cy Katzen Humanitarian Award, 2014
- Federal Laboratory Consortium Award for Excellence in Technology Transfer, 2010
- NIH APAO Outstanding Achievement Award, 1999
- Gordon F. Vawter Award, Society for Pediatric Pathology, 1996
- NCI New Invention and Technology Development Award, 1995
- American Society of Clinical Pathologists Resident Award in Anatomic Pathology, 1994
- Stowell-Orbison Award for Pathologist-in-training, U.S. and Canadian Academy of Pathology, 1994
There are no open positions at this time. Check back again later, or take a look at CCR's Careers page.